Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)
Key Insights
- The projected fair value for Genomma Lab Internacional. de is Mex$21.54 based on 2 Stage Free Cash Flow to Equity
- With Mex$20.48 share price, Genomma Lab Internacional. de appears to be trading close to its estimated fair value
- The Mex$20.00 analyst price target for LAB B is 7.1% less than our estimate of fair value
How far off is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. The Discounted Cash Flow (DCF) model is the tool we will apply to do this. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.
Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model.
See our latest analysis for Genomma Lab Internacional. de
The Method
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value:
10-year free cash flow (FCF) forecast
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (MX$, Millions) | Mex$2.46b | Mex$1.91b | Mex$1.64b | Mex$1.52b | Mex$1.47b | Mex$1.48b | Mex$1.52b | Mex$1.58b | Mex$1.67b | Mex$1.77b |
Growth Rate Estimate Source | Analyst x2 | Analyst x1 | Est @ -14.02% | Est @ -7.44% | Est @ -2.83% | Est @ 0.39% | Est @ 2.65% | Est @ 4.23% | Est @ 5.34% | Est @ 6.11% |
Present Value (MX$, Millions) Discounted @ 13% | Mex$2.2k | Mex$1.5k | Mex$1.1k | Mex$927 | Mex$797 | Mex$707 | Mex$642 | Mex$592 | Mex$551 | Mex$517 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = Mex$9.5b
We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 7.9%. We discount the terminal cash flows to today's value at a cost of equity of 13%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = Mex$1.8b× (1 + 7.9%) ÷ (13%– 7.9%) = Mex$37b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= Mex$37b÷ ( 1 + 13%)10= Mex$11b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is Mex$20b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Relative to the current share price of Mex$20.5, the company appears about fair value at a 4.9% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.
Important Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Genomma Lab Internacional. de as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 13%, which is based on a levered beta of 0.800. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Genomma Lab Internacional. de
- Debt is well covered by earnings and cashflows.
- Dividends are covered by earnings and cash flows.
- Earnings declined over the past year.
- Dividend is low compared to the top 25% of dividend payers in the Pharmaceuticals market.
- Annual earnings are forecast to grow faster than the Mexican market.
- Current share price is below our estimate of fair value.
- Annual revenue is forecast to grow slower than the Mexican market.
Moving On:
Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For Genomma Lab Internacional. de, we've compiled three pertinent factors you should consider:
- Risks: Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Genomma Lab Internacional. de , and understanding them should be part of your investment process.
- Future Earnings: How does LAB B's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the BMV every day. If you want to find the calculation for other stocks just search here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BMV:LAB B
Genomma Lab Internacional. de
Provides pharmaceutical and personal care products primarily in Latin America.
Excellent balance sheet and good value.